-+ 0.00%
-+ 0.00%
-+ 0.00%

Virax Biolabs FY26 net loss narrows to $5.03 million; revenue more than doubled to $12,423

PUBT·07/06/2026 10:11:23
Listen to the news
Virax Biolabs FY26 net loss narrows to $5.03 million; revenue more than doubled to $12,423
  • Virax Biolabs posted a net loss of USD 5.03 million, narrowing from USD 6.07 million a year earlier.
  • Operating loss widened to USD 6.4 million from USD 6.08 million, while revenue more than doubled to USD 12,423.
  • Research and development expense climbed to USD 3.74 million from USD 2.03 million, while general and administrative costs fell to USD 2.67 million from USD 3.99 million.
  • Income tax benefit rose to USD 900,240 from USD 136,661, reflecting research and development tax credits.
  • Cash ended the year at USD 6.44 million, up from USD 4.23 million, as financing inflows increased to USD 7.09 million from USD 5.81 million.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Virax Biolabs Group Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-295158), on July 06, 2026, and is solely responsible for the information contained therein.